Phase I/II Trial of Letrozole (Femara) and Sorafenib (Nexavar) in Postmenopausal Women With Hormone-Receptor Positive Locally Advanced or Metastatic Breast Cancer.
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 20 Jun 2018
At a glance
- Drugs Letrozole (Primary) ; Sorafenib (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 13 Jun 2018 Planned End Date changed from 1 May 2018 to 1 May 2019.
- 13 Jun 2018 Planned primary completion date changed from 1 May 2018 to 1 May 2019.
- 10 Jun 2017 Biomarkers information updated
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History